Human pluripotent stem cells in drug discovery and predictive toxicology.
暂无分享,去创建一个
Marc Peschanski | M. Peschanski | D. Laustriat | Jacqueline Gide | Delphine Laustriat | Jacqueline Gide
[1] J. Kramer,et al. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates , 2007, Nature Reviews Drug Discovery.
[2] S. Palecek,et al. Scalable culture and cryopreservation of human embryonic stem cells on microcarriers , 2009, Biotechnology progress.
[3] Wenjun Guo,et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds , 2008, Nature Biotechnology.
[4] J. Utikal,et al. Induced Pluripotent Stem Cells Generated Without Viral Integration , 2008, Science.
[5] T. Hartung,et al. First steps in establishing a developmental toxicity test method based on human embryonic stem cells. , 2008, Toxicology in vitro : an international journal published in association with BIBRA.
[6] S. Rechitsky,et al. Preimplantation genetic diagnosis as a source of human embryonic stem cell lines with genetic disorders , 2008 .
[7] M. Schuldiner,et al. Modeling for Lesch‐Nyhan Disease by Gene Targeting in Human Embryonic Stem Cells , 2004, Stem cells.
[8] Jehyuk Lee,et al. Generation of functional human hepatic endoderm from human induced pluripotent stem cells , 2009, Hepatology.
[9] J. Thomson,et al. Embryonic stem cell lines derived from human blastocysts. , 1998, Science.
[10] B. Thiers. Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2008 .
[11] M. Peschanski,et al. Human embryonic stem cells reveal recurrent genomic instability at 20q11.21 , 2008, Nature Biotechnology.
[12] B. Jernström,et al. Glutathione transferases in hepatocyte-like cells derived from human embryonic stem cells. , 2007, Toxicology in vitro : an international journal published in association with BIBRA.
[13] Hynek Wichterle,et al. Induced Pluripotent Stem Cells Generated from Patients with ALS Can Be Differentiated into Motor Neurons , 2008, Science.
[14] K. Sermon,et al. Recurrent chromosomal abnormalities in human embryonic stem cells , 2008, Nature Biotechnology.
[15] Peter Sartipy,et al. The application of human embryonic stem cell technologies to drug discovery. , 2007, Drug discovery today.
[16] A. Khanna,et al. Assessment of drug induced developmental toxicity using human embryonic stem cells , 2008, Cell biology international.
[17] Magnus Ingelman-Sundberg,et al. Hepatocyte-like cells derived from human embryonic stem cells specifically via definitive endoderm and a progenitor stage. , 2010, Journal of biotechnology.
[18] H. Thomson,et al. Bioprocessing of embryonic stem cells for drug discovery. , 2007, Trends in biotechnology.
[19] S. Fisher,et al. Human embryonic stem cells as a model system for studying the effects of smoke exposure on the embryo. , 2008, Reproductive toxicology.
[20] David C Hay,et al. Efficient Differentiation of Hepatocytes from Human Embryonic Stem Cells Exhibiting Markers Recapitulating Liver Development In Vivo , 2008, Stem cells.
[21] S. Pickering,et al. Preimplantation genetic diagnosis as a novel source of embryos for stem cell research. , 2003, Reproductive biomedicine online.
[22] Marc Peschanski,et al. Improvement of culture conditions of human embryoid bodies using a controlled perfused and dialyzed bioreactor system. , 2008, Tissue engineering. Part C, Methods.
[23] T Seidle,et al. The development of new concepts for assessing reproductive toxicity applicable to large scale toxicological programmes. , 2007, Current pharmaceutical design.
[24] Dong Wook Han,et al. Generation of induced pluripotent stem cells using recombinant proteins. , 2009, Cell stem cell.
[25] David A. Katz,et al. Defining drug disposition determinants: a pharmacogenetic–pharmacokinetic strategy , 2008, Nature Reviews Drug Discovery.
[26] O. Yanuka,et al. Developmental study of fragile X syndrome using human embryonic stem cells derived from preimplantation genetically diagnosed embryos. , 2007, Cell stem cell.
[27] F. Larcher,et al. Human embryonic stem-cell derivatives for full reconstruction of the pluristratified epidermis: a preclinical study , 2009, The Lancet.
[28] J. Mcneish. Stem cells as screening tools in drug discovery. , 2007, Current opinion in pharmacology.
[29] S. Yamanaka,et al. Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.
[30] James A. Thomson,et al. Induced pluripotent stem cells from a spinal muscular atrophy patient , 2009, Nature.
[31] M. S. Kallos,et al. Large-scale expansion of pluripotent human embryonic stem cells in stirred-suspension bioreactors. , 2010, Tissue engineering. Part C, Methods.
[32] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[33] D. Kehoe,et al. Scalable stirred-suspension bioreactor culture of human pluripotent stem cells. , 2010, Tissue engineering. Part A.
[34] S. Bremer,et al. Hazard assessment of methylmercury toxicity to neuronal induction in embryogenesis using human embryonic stem cells. , 2009, Toxicology.
[35] A. Viale,et al. Modeling Pathogenesis and Treatment of Familial Dysautonomia using Patient Specific iPSCs , 2009, Nature.
[36] Aldert Piersma,et al. The ECVAM International Validation Study on In Vitro Embryotoxicity Tests: Results of the Definitive Phase and Evaluation of Prediction Models , 2002, Alternatives to laboratory animals : ATLA.
[37] S. Flora,et al. Monoisoamyl dimercaptosuccinic acid abrogates arsenic-induced developmental toxicity in human embryonic stem cell-derived embryoid bodies: comparison with in vivo studies. , 2009, Biochemical pharmacology.
[38] J. Crook,et al. Human stem cells for modeling neurological disorders: Accelerating the drug discovery pipeline , 2008, Journal of cellular biochemistry.
[39] Susanne Bremer,et al. Validation of the Embryonic Stem Cell Test in the International ECVAM Validation Study on Three In Vitro Embryotoxicity Tests , 2004, Alternatives to laboratory animals : ATLA.
[40] H Nau,et al. Species differences in pharmacokinetics and drug teratogenesis. , 1986, Environmental health perspectives.
[41] Oliver Brüstle,et al. Automated maintenance of embryonic stem cell cultures , 2007, Biotechnology and bioengineering.
[42] P. Devroey,et al. Derivation of human embryonic stem cell lines from embryos obtained after IVF and after PGD for monogenic disorders. , 2006, Human reproduction.
[43] J. Mcneish. Embryonic stem cells in drug discovery , 2004, Nature Reviews Drug Discovery.
[44] C. Pouton,et al. Pharmaceutical applications of embryonic stem cells. , 2005, Advanced drug delivery reviews.
[45] H. Green,et al. Marker succession during the development of keratinocytes from cultured human embryonic stem cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[46] R. Eiges,et al. PGD-derived human embryonic stem cell lines as a powerful tool for the study of human genetic disorders , 2008, Molecular and Cellular Endocrinology.
[47] T. Ichisaka,et al. Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2007, Cell.
[48] Robert Lanza,et al. Efficient Differentiation of Functional Hepatocytes from Human Embryonic Stem Cells , 2008, Stem cells.
[49] Frank Stahl,et al. Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[50] C Mason,et al. Preimplantation genetic diagnosis as a source of human embryonic stem cells for disease research and drug discovery , 2009, BJOG : an international journal of obstetrics and gynaecology.
[51] H. Baharvand,et al. Human-induced pluripotent stem cells: derivation, propagation, and freezing in serum- and feeder layer-free culture conditions. , 2010, Methods in molecular biology.